TABLE 1.
Individual efficacy indicators at baseline in the HS016 and adalimumab groups.
| Indicator a | HS016 (n = 416) | Adalimumab (n = 232) | p-value |
|---|---|---|---|
| Total back pain score (0–10 cm NRS) | 6.78 ± 1.61 | 7.00 ± 1.60 | 0.092 |
| Nocturnal back pain score (0–10 cm NRS) | 6.66 ± 1.80 | 6.90 ± 1.94 | 0.114 |
| SJC (46 joints) | 0.24 ± 1.00 | 0.37 ± 2.30 | 0.312 |
| MASES (range 0–13) | 1.58 ± 2.26 | 1.76 ± 2.41 | 0.355 |
| PaGA of disease activity (0–10 cm NRS) | 6.80 ± 1.58 | 6.96 ±1.64 | 0.212 |
| PhGA of disease activity (0–10 cm NRS) | 6.28 ± 1.46 | 6.37 ± 1.47 | 0.452 |
| BASDAI | 6.24 ± 1.30 | 6.33 ± 1.38 | 0.401 |
| BASFI | 4.57 ± 2.30 | 4.71 ± 2.37 | 0.467 |
| BASMIlin | 1.26 ± 1.66 | 1.13 ± 1.62 | 0.311 |
| BASMIlin_lateral spinal flexion | 5.40 ± 2.67 | 5.28 ± 2.75 | 0.568 |
| BASMIlin_tragus to wall distance | 1.90 ± 1.70 | 1.70 ± 1.47 | 0.128 |
| BASMIlin_lumbar flexion | −8.04 ± 2.82 | −8.37 ± 2.68 | 0.148 |
| BASMIlin_maximal intermalleolar distance | 2.55 ± 2.27 | 2.65 ± 2.32 | 0.576 |
| BASMIlin_cervical rotation | 4.49 ± 2.13 | 4.37 ± 1.95 | 0.485 |
| Chest expansion (cm) | 3.60 ± 1.99 | 3.59 ± 1.84 | 0.940 |
BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMIlin, linear Bath ankylosing spondylitis metrology index; MASES, Maastricht ankylosing spondylitis enthesitis score; NRS, numerical rating scale; PaGA, Patient global assessment; PhGA, Physician global assessment; SJC, swollen joint count.
a
All data are presented as the mean ± SD.